GGrantIndex
← Leaderboards

Eugenia Trushina

Mayo Clinic Rochester

$15,385,253
Attributed
$17,966,870
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY201125
$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,966,870 · 7

By mechanism

RF1$10,163,768 · 2
R01$5,955,179 · 3
UH3$1,062,867 · 1
UG3$785,056 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposMitochondriaS DiseaseNeuronsIn VivoProteinsMetabolicGeneticFunctional DisorderMolecularBaseMouse ModelOxidation-ReductionPathway InteractionsNerve DegenerationNeurodegenerative DisordersBiological MarkersMitochondrial DysfunctionCognitive FunctionAnimal ModelPre-ClinicalInflammationPharmaceutical PreparationsCells

Grant awards (25)

Mitochondrial Complex I as a Target for Neuroprotection in AD$1,458,379
RF1 · FY2025 · AG · contact PI
Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.$397,500
R01 · FY2024 · AG
Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.$397,500
R01 · FY2023 · AG
Mitochondrial Complex I as a Target for Neuroprotection in AD$2,271,860
RF1 · FY2022 · AG · contact PI
Small Molecule Mitochondria-Targeted Therapeutics for AD$778,431
UH3 · FY2022 · NS · contact PI
Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.$397,500
R01 · FY2022 · AG
Small Molecule Mitochondria-Targeted Therapeutics for AD (Supplement)$284,436
UH3 · FY2022 · NS · contact PI
Small molecule mitochondria-targeted therapeutics for AD$785,056
UG3 · FY2021 · NS · contact PI
Small molecule mitochondria-targeted therapeutics for Huntingtons Disease$535,142
R01 · FY2021 · NS · contact PI
Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.$397,500
R01 · FY2021 · AG
Small molecule mitochondria-targeted therapeutics for Huntingtons Disease$535,142
R01 · FY2020 · NS · contact PI
Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.$397,500
R01 · FY2020 · AG
AMP-Kinase as a target for neuroprotection in AD$3,175,735
RF1 · FY2019 · AG
Small molecule mitochondria-targeted therapeutics for Huntingtons Disease$545,636
R01 · FY2019 · NS · contact PI
Small molecule mitochondria-targeted therapeutics for Huntingtons Disease$545,636
R01 · FY2018 · NS · contact PI
Mitochondrial Complex I as a Target for Neuroprotection in AD$66,462
RF1 · FY2018 · AG · contact PI
Mitochondrial Complex I as a Target for Neuroprotection in AD$3,191,332
RF1 · FY2017 · AG · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$305,930
R01 · FY2015 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$302,870
R01 · FY2014 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$157,410
R01 · FY2014 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$111,300
R01 · FY2014 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$299,811
R01 · FY2013 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$16,942
R01 · FY2013 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$305,930
R01 · FY2012 · ES · contact PI
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disorders$305,930
R01 · FY2011 · ES · contact PI